Philips has backed two artificial intelligence (AI) projects as part of cross-sector collaborations with the NHS, academia and industry partners from the Government’s Industrial Strategy Challenge Fund, delivered through United Kingdom Research and Innovation (UKRI).
The Government has announced five AI centres of excellence across the UK. Philips are a part of the I-CAIRD project based in Glasgow, and PathLAKE based in Coventry. These two projects will last for three years and commence in December 2018.
The projects are part of the digitisation of pathology services and accelerates the development of AI software to support cancer diagnostics as it’s developed and adopted in health in a bid to improve patient care with better and faster cancer diagnostics and treatment.
The company will be the principle partner of PathLAKE which partners from University Hospitals Coventry and Warwickshire NHS Trust and teaching hospitals and universities at Warwick, Belfast, Oxford and Nottingham – who will aim to embed and demonstrate the diagnostic efficiency of digital pathology, computer aided testing of pathology samples, and develop AI tools to personalised medicine. The NHS pathology data from the project could be used to drive health-related economic growth in AI.
Professor David Snead from University Hospitals Coventry and Warwickshire NHS Trust said: “These technologies will be key to our understanding and utilisation of clinical information. The knowledge PathLAKE will unlock, both in the short and long-term future, will completely change cancer care in the NHS while embedding a world-leading life-sciences and technology sector in our health system.”
The I-CAIRD (Industrial Centre for Artificial Intelligence Research in Digital Diagnostics) project at Glasgow’s Queen Elizabeth University Hospital – which will bring together clinicians, health planners and industry to work with innovative SME’s to answer clinical questions with the aim of solving healthcare challenges more quickly and efficiently.
The digital pathology technology together with AI will be used by clinicians to help diagnose gynaecological cancers earlier and more definitively in a bid to prove outcomes and patient survival rates.
Gareth Bryson, a pathologist, said: “At Queen Elizabeth University Hospital, we’re committed to providing the best possible care for our patients. We’ve already been working with Philips to develop a national digital pathology programme and this welcome investment will help us, along with industry partner support, to improve the speed, efficiency and specificity of vitally important artificial intelligence applications, so our staff can be confident in offering patients the best treatment as soon as possible.”
Neil Mesher, CEO for Philips UKI added: “Philips has been fully invested in the Government’s Life Sciences Industry Strategy from the outset and now has two opportunities to build strong partnerships that will drive improved patient care in the UK for years to come. Philips sees this as not only an opportunity to invest in improved and earlier diagnostics for patients via AI in pathology services but also as a new day for collaborative, cross-partner working that will ensure a future-proofed, world-class NHS. We are honoured to be part of what will undoubtedly be an exciting three years in digital diagnostics and personalised medicine discovery.”